Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites

Ann Hematol. 2012 Sep;91(9):1499-500. doi: 10.1007/s00277-012-1410-9. Epub 2012 Jan 28.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived / blood
  • Antibodies, Monoclonal, Murine-Derived / pharmacokinetics*
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Agents / blood
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Ascites / drug therapy
  • Ascites / etiology
  • Ascites / metabolism*
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Humans
  • Lymphoma, Follicular / complications
  • Lymphoma, Follicular / drug therapy*
  • Male
  • Prednisone / administration & dosage
  • Recurrence
  • Remission Induction
  • Rituximab
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol